Publications

Anti-cancer drugs

Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.

01-09-2016

Cancer chemotherapy and pharmacology

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.

01-06-2016

Journal of pharmacokinetics and pharmacodynamics

The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.

01-06-2016

European journal of clinical pharmacology

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment.

01-06-2016

British journal of clinical pharmacology

Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

01-05-2016

Journal of neurology

Strategies to target drugs to gliomas and CNS metastases of solid tumors.

01-03-2016

The AAPS journal

Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.

01-03-2016

Obesity surgery

Proton Pump Inhibitor Prophylaxis After Gastric Bypass Does Not Cause Hypomagnesemia.

01-03-2016

Lung cancer (Amsterdam, Netherlands)

Crizotinib-induced fatal fulminant liver failure.

01-03-2016

Haematologica

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

01-03-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.

15-02-2016

European journal of cancer (Oxford, England : 1990)

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.

01-02-2016

Cancers

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.

02-01-2016

Bioanalysis

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

15-12-2015

Cancer treatment reviews

The use of combinations of monoclonal antibodies in clinical oncology.

01-12-2015

Investigational new drugs

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.

01-12-2015

Journal of cancer research and clinical oncology

Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.

01-10-2015

British journal of clinical pharmacology

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

01-08-2015

Clinical pharmacokinetics

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.

01-08-2015

CPT: pharmacometrics & systems pharmacology

Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin.

01-07-2015

Clinical lung cancer

Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.

01-07-2015

CPT: pharmacometrics & systems pharmacology

Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.

01-07-2015

JAMA oncology

Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil.

01-06-2015

British journal of clinical pharmacology

Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

01-05-2015

BioMed research international

Corrigendum to "Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy".

30-04-2015

Pharmacology research & perspectives

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.

01-03-2015

European journal of clinical pharmacology

Baclofen overdose treated with continuous venovenous hemofiltration.

01-03-2015

International journal of pharmaceutics

Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.

01-02-2015

Investigational new drugs

Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.

01-02-2015

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Dosing of carboplatin in a patient with amputated legs: A case report.

01-12-2014

Pediatric blood & cancer

Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation.

01-12-2014

Drugs & aging

Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study.

01-10-2014

Investigational new drugs

Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error.

01-10-2014

Annals of oncology : official journal of the European Society for Medical Oncology

Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

01-10-2014

Nederlands tijdschrift voor geneeskunde

[Hyperglycaemia during treatment with everolimus].

15-08-2014

Clinical pharmacology and therapeutics

Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.

01-07-2014

Therapeutic drug monitoring

Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.

01-06-2014

British journal of cancer

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

13-05-2014

Current clinical pharmacology

Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer.

01-05-2014

Clinical pharmacokinetics

Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.

01-04-2014

BioMed research international

Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy.

29-03-2014

Clinical pharmacokinetics

Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study.

01-03-2014

Journal of pharmaceutical sciences

Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling.

01-02-2014

BMC cancer

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.

28-12-2013

European journal of clinical pharmacology

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.

01-12-2013

Gynecologic oncology

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.

01-09-2013

British journal of clinical pharmacology

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

01-09-2013

Medical decision making : an international journal of the Society for Medical Decision Making

Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in R.

01-08-2013

Journal of clinical pharmacology

A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors.

01-08-2013

British journal of clinical pharmacology

Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

01-07-2013

Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.

The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment.

Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.

Proton Pump Inhibitor Prophylaxis After Gastric Bypass Does Not Cause Hypomagnesemia.

Crizotinib-induced fatal fulminant liver failure.

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

The use of combinations of monoclonal antibodies in clinical oncology.

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.

Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.

Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin.

Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.

Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.

Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil.

Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

Corrigendum to "Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy".

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.

Baclofen overdose treated with continuous venovenous hemofiltration.

Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.

Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.

Dosing of carboplatin in a patient with amputated legs: A case report.

Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation.

Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study.

Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error.

Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

[Hyperglycaemia during treatment with everolimus].

Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.

Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer.

Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.

Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy.

Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study.

Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling.

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in R.

A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors.

Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

This site uses cookies